Insulin glargine

Drug ingredient

CAS 160337-95-1

This chemical is an active pharmaceutical ingredient used in FDA-regulated drugs.

US productionNot reported

Import value, 2024$16.4B

Top sourceIreland 94%

This chemical is not on EPA’s Toxic Substances Control Act inventory, the list behind EPA’s production survey.

Why supply is unknown

Production is reported production, not a complete census of factories. Import value and source-country shares describe a shared customs category, not a separate chemical measurement.

Where It Comes From

Customs basis: HS 293719 · basket

These shares come from HS customs code 293719, which covers 53 tracked chemicals in total. They estimate the category's origin mix, not this chemical specifically.

Source Countries

Country of origin for US imports, from Census customs data (2024).

IE 94%IrelandAR 4%ArgentinaCN 1%ChinaDK 1%Denmark

Switzerland
Sweden
India
Spain
Israel
Austria
Belgium
Netherlands
Italy
Hong Kong
Brazil
United Kingdom
Germany
Canada
Australia
Japan
New Zealand
Latvia
South Korea
Taiwan
Estonia
Uruguay

11 FDA-registered drug labelers

A-S Medication Solutions

Amphastar Nanjing Pharmaceuticals, Inc.

Biocon Biologics Inc.

Biocon Limited

Civica, Inc.

Eli Lilly and Company

Eli Lilly Italia SPA

Hefei Xinzhu Biological Technology Co., Ltd.

Lilly France

Professional Complementary Health Formulas

Sanofi-Aventis U.S. LLC

Why It Matters

Sectors

Health

Downstream Uses

Appears in 14 drug and cosmetic product listings (FDA).

•Insulin Glargine
•Basaglar Tempo Pen
•Rezvoglar KwikPen
•Soliqua 100/33
•Lantus
•Toujeo Max
•Semglee
•Toujeo

Show all 14

•Insulin glargine U-300
•Insulin 1556
•Insulin glargine U-300 Max
•Basaglar KwikPen
•Lantus Solostar
•Insulin Glargine Solostar

FDA Shortage Status

Whether any manufacturer currently reports this drug as in shortage on the FDA Drug Shortages database. "Active Shortage" means at least one presentation has status "current."

No Shortage

Shortage History

Rows group FDA shortage filings by drug product. Each manufacturer makes its own FDA shortage filing, so one product can carry several reports at once: Available, Limited Availability, Unavailable or to be discontinued.

to be discontinued
Insulin Glargine Injection
Shortage listed since October 24, 2025

See all current drug shortages

Chemical Identity

CAS160337-95-1

PubChem CID118984454

DTXSIDDTXSID0043927

FormulaC267H404N72O78S6

Mol. Weight6063 g/mol

SMILESCCC(C)C1C(=O)NC2CSSCC(C(=O)NC(CSSCC(C(=O)NCC(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(CSSCC(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC2=O)CO)CC(C)C)CC3=CC=C(C=C3)O)CCC(=O)N)CC(C)C)CCC(=O)O)CC(=O)N)CC4=CC=C(C=C4)O)C(=O)NCC(=O)O)C(=O)NCC(=O)NC(CCC(=O)O)C(=O)NC(CCCNC(=N)N)C(=O)NCC(=O)NC(CC5=CC=CC=C5)C(=O)NC(CC6=CC=CC=C6)C(=O)NC(CC7=CC=C(C=C7)O)C(=O)NC(C(C)O)C(=O)N8CCCC8C(=O)NC(CCCCN)C(=O)NC(C(C)O)C(=O)NC(CCCNC(=N)N)C(=O)NC(CCCNC(=N)N)C(=O)O)C(C)C)CC(C)C)CC9=CC=C(C=C9)O)CC(C)C)C)CCC(=O)O)C(C)C)CC(C)C)CC2=CNC=N2)CO)NC(=O)C(CC(C)C)NC(=O)C(CC2=CNC=N2)NC(=O)C(CCC(=O)N)NC(=O)C(CC(=O)N)NC(=O)C(C(C)C)NC(=O)C(CC2=CC=CC=C2)N)C(=O)NC(C(=O)NC(C(=O)N1)CO)C(C)O)NC(=O)C(CCC(=O)N)NC(=O)C(CCC(=O)O)NC(=O)C(C(C)C)NC(=O)C(C(C)CC)NC(=O)CN

Data Sources

PubChem · compound 118984454Retrieved 2026-04-07
FDA National Drug Code directoryRetrieved 2026-04-25
FDA Drug ShortagesRetrieved 2026-10-04
US Census international tradeReporting year: 2024 · Retrieved 2026-10-04

← Back to Dashboard ← Back to Health

Brief citations

Insulin glargine (CAS 160337-95-1) https://chemicalindependence.com/chemical/160337-95-1/ PubChem: 118984454. Retrieved 2026-04-07. https://pubchem.ncbi.nlm.nih.gov/compound/118984454 FDA National Drug Code directory: CAS 160337-95-1. Retrieved 2026-04-25. https://open.fda.gov/data/ndc/ FDA Drug Shortages: CAS 160337-95-1. Retrieved 2026-10-04. https://www.accessdata.fda.gov/scripts/drugshortages/ US Census international trade: HS 293719 for CAS 160337-95-1. Reporting year: 2024. https://usatrade.census.gov/